{"database": "lobbying", "table": "lobbying_activities", "rows": [[3239642, "ec1641e6-47ed-4b96-9371-5ea3be5c49a9", "Q3", "ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC)", 1466, "ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC)", 2024, "third_quarter", "MED", "* On July 7, ADLM joined with other healthcare providers in supporting a resolution to employ the Congressional Review Act as it pertains to the FDAs Proposed Rule, Docket No. FDA-2023-N-2177, Medical Devices: Laboratory Developed Tests. * On September 5, ADLM wrote to House and Senate leaders providing survey results indicating the clinical laboratories will have problems complying with the FDA final rule regulating LDTs. * On August 15 and September 4, ADLM initiated grassroots campaigns urging House and Senate members to support future legislative efforts to revoke the FDA LDT final rule. * On September 10th, ADLM participating in Rare Disease Congress Caucus outlining concern about FDA LDT final rule.", "HOUSE OF REPRESENTATIVES,SENATE", null, 60000, 0, 0, "2024-10-16T10:32:59-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3239642"], "units": {}, "query_ms": 0.37353194784373045, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}